Cargando…

Time since menopause and skeletal muscle estrogen receptors, PGC-1α, and AMPK

OBJECTIVE: Short-term administration of estradiol (E(2)) improves insulin-stimulated glucose disposal rate in early postmenopausal (EPM) women compared with a reduction in late postmenopausal (LPM) women. The underlying mechanisms by which E(2) action on glucose disposal rate reversed from beneficia...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Young-Min, Pereira, Rocio I., Erickson, Christopher B., Swibas, Tracy A., Kang, Chounghun, Van Pelt, Rachael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott-Raven Publishers 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484730/
https://www.ncbi.nlm.nih.gov/pubmed/28195989
http://dx.doi.org/10.1097/GME.0000000000000829
_version_ 1783245932053135360
author Park, Young-Min
Pereira, Rocio I.
Erickson, Christopher B.
Swibas, Tracy A.
Kang, Chounghun
Van Pelt, Rachael E.
author_facet Park, Young-Min
Pereira, Rocio I.
Erickson, Christopher B.
Swibas, Tracy A.
Kang, Chounghun
Van Pelt, Rachael E.
author_sort Park, Young-Min
collection PubMed
description OBJECTIVE: Short-term administration of estradiol (E(2)) improves insulin-stimulated glucose disposal rate in early postmenopausal (EPM) women compared with a reduction in late postmenopausal (LPM) women. The underlying mechanisms by which E(2) action on glucose disposal rate reversed from beneficial early to harmful late in menopause is unknown, but might include adverse changes in estrogen receptors (ERs) or other biomarkers of cellular energy metabolism with age or duration of estrogen deficiency. METHODS: We retrospectively analyzed skeletal muscle samples from 27 postmenopausal women who were 6 years or less past menopause (EPM; n = 13) or at least 10 years past menopause (LPM; n = 14). Fasted skeletal muscle (vastus lateralis) samples were collected after 1 week administration of transdermal E(2) or placebo, in random cross-over design. RESULTS: Compared with EPM, LPM had reduced skeletal muscle ERα and ERβ nuclear protein. Short-term E(2) treatment did not change nuclear ERα or ERβ, but decreased cytosolic ERα, so the proportion of ERα in the nucleus compared with the cytosol tended to increase. There was a group-by-treatment interaction (P < 0.05) for nuclear proliferator-activated receptor γ co-activator 1-α and phosphorylated adenosine monophosphate-activated protein kinase, such that E(2) increased these proteins in EPM, but decreased these proteins in LPM. CONCLUSIONS: These preliminary studies of skeletal muscle from early and late postmenopausal women treated with E(2) suggest there may be declines in skeletal muscle ER and changes in the E(2)-mediated regulation of cellular energy homeostasis with increasing time since menopause.
format Online
Article
Text
id pubmed-5484730
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott-Raven Publishers
record_format MEDLINE/PubMed
spelling pubmed-54847302017-10-24 Time since menopause and skeletal muscle estrogen receptors, PGC-1α, and AMPK Park, Young-Min Pereira, Rocio I. Erickson, Christopher B. Swibas, Tracy A. Kang, Chounghun Van Pelt, Rachael E. Menopause Original Articles OBJECTIVE: Short-term administration of estradiol (E(2)) improves insulin-stimulated glucose disposal rate in early postmenopausal (EPM) women compared with a reduction in late postmenopausal (LPM) women. The underlying mechanisms by which E(2) action on glucose disposal rate reversed from beneficial early to harmful late in menopause is unknown, but might include adverse changes in estrogen receptors (ERs) or other biomarkers of cellular energy metabolism with age or duration of estrogen deficiency. METHODS: We retrospectively analyzed skeletal muscle samples from 27 postmenopausal women who were 6 years or less past menopause (EPM; n = 13) or at least 10 years past menopause (LPM; n = 14). Fasted skeletal muscle (vastus lateralis) samples were collected after 1 week administration of transdermal E(2) or placebo, in random cross-over design. RESULTS: Compared with EPM, LPM had reduced skeletal muscle ERα and ERβ nuclear protein. Short-term E(2) treatment did not change nuclear ERα or ERβ, but decreased cytosolic ERα, so the proportion of ERα in the nucleus compared with the cytosol tended to increase. There was a group-by-treatment interaction (P < 0.05) for nuclear proliferator-activated receptor γ co-activator 1-α and phosphorylated adenosine monophosphate-activated protein kinase, such that E(2) increased these proteins in EPM, but decreased these proteins in LPM. CONCLUSIONS: These preliminary studies of skeletal muscle from early and late postmenopausal women treated with E(2) suggest there may be declines in skeletal muscle ER and changes in the E(2)-mediated regulation of cellular energy homeostasis with increasing time since menopause. Lippincott-Raven Publishers 2017-07 2017-06-26 /pmc/articles/PMC5484730/ /pubmed/28195989 http://dx.doi.org/10.1097/GME.0000000000000829 Text en © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The North American Menopause Society. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Original Articles
Park, Young-Min
Pereira, Rocio I.
Erickson, Christopher B.
Swibas, Tracy A.
Kang, Chounghun
Van Pelt, Rachael E.
Time since menopause and skeletal muscle estrogen receptors, PGC-1α, and AMPK
title Time since menopause and skeletal muscle estrogen receptors, PGC-1α, and AMPK
title_full Time since menopause and skeletal muscle estrogen receptors, PGC-1α, and AMPK
title_fullStr Time since menopause and skeletal muscle estrogen receptors, PGC-1α, and AMPK
title_full_unstemmed Time since menopause and skeletal muscle estrogen receptors, PGC-1α, and AMPK
title_short Time since menopause and skeletal muscle estrogen receptors, PGC-1α, and AMPK
title_sort time since menopause and skeletal muscle estrogen receptors, pgc-1α, and ampk
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484730/
https://www.ncbi.nlm.nih.gov/pubmed/28195989
http://dx.doi.org/10.1097/GME.0000000000000829
work_keys_str_mv AT parkyoungmin timesincemenopauseandskeletalmuscleestrogenreceptorspgc1aandampk
AT pereirarocioi timesincemenopauseandskeletalmuscleestrogenreceptorspgc1aandampk
AT ericksonchristopherb timesincemenopauseandskeletalmuscleestrogenreceptorspgc1aandampk
AT swibastracya timesincemenopauseandskeletalmuscleestrogenreceptorspgc1aandampk
AT kangchounghun timesincemenopauseandskeletalmuscleestrogenreceptorspgc1aandampk
AT vanpeltrachaele timesincemenopauseandskeletalmuscleestrogenreceptorspgc1aandampk